Phase 2
N=38
Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection
Acute Respiratory Infection
Bottom Line
View on ClinicalTrials.gov: NCT01114581 ↗Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Oct 2012
Primary outcome: Primary: Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs — 21.4; 23.1 Percentage of inhaled radioactive tracer
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Mucinex (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Reckitt Benckiser LLC
- Primary completion
- Apr 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs |
21.4; 23.1 | — |
| SECONDARY Guaifenesin AUC(0-3) |
4060 | — |
| SECONDARY Assess Sputum Properties (Objective Measures) and Symptoms (Subjective Measures) After Treatment With Mucinex or Placebo. |
— | — |
Summary
The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.
Eligibility Criteria
Inclusion Criteria
- Symptoms of cough, thickened mucus and chest congestion
- Able to produce sputum
- Non Smoker
Exclusion Criteria
- Pregnant
- Smokers
- Fever above 101°F
- Any chronic illness
Data sourced from ClinicalTrials.gov (NCT01114581). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.